Anne Bruinvels joins EPEMED as executive director
Targeted with growing start-up organisation and building its strategic framework
Bruinvels will be responsible for growing the start-up organisation and, together with the board of directors, for building its strategic framework in creating guidance for all those involved in progressing personalised medicine with an emphasis on European market challenges.
‘I'm delighted to join EPEMED's board and to lead the association to facilitate the development and introduction of personalised medicine in Europe. I'm looking forward to working with the different parties worldwide involved in making real progress in this field,’ said Bruinvels.
Bruinvels started her work in personalised medicine more than 10 years ago. She previously founded Elixior, a personalised healthcare advisory company and prior to that Curidium, a personalised medicine company identifying companion diagnostics and therapeutics to treat patients with central nervous system disorders. She was Curidium's ceo for more than six years and raised several rounds of funding before taking the company public on the AIM of the London Stock Exchange.
Bruinvels has also worked in research for various pharmaceutical companies, including SmithKline Beecham, Wyeth and Sandoz Pharma.
You may also like
Digital
![Shilpa Biologicals launches PartnerPower real-time visibility platform for biologics CDMO operations]()
Shilpa Biologicals launches PartnerPower real-time visibility platform for biologics CDMO operations
The digital data fabric links R&D, analytical development and GMP manufacturing, replacing periodic reporting with continuous audit-ready transparency aligned to FDA, EMA and PMDA expectations
Manufacturing
![Piramal Pharma Solutions highlights strong performance across more than 200 customer audits]()
Piramal Pharma Solutions highlights strong performance across more than 200 customer audits
Piramal Pharma Solutions completed more than 200 customer audits and received over 70 approvals from regulatory agencies across its global network over the past year, with strong overall outcomes
Regulatory
![Pheno Therapeutics gains FDA IND clearance for first-in-class GPR17 antagonist PTD802 in MS]()
Pheno Therapeutics gains FDA IND clearance for first-in-class GPR17 antagonist PTD802 in MS
The clearance enables a first-in-human trial of the UCB-licensed remyelination candidate, marking the first GPR17 programme to reach clinical development for multiple sclerosis and related demyelinating diseases
Research & Development
![Promega UK Launches Lumit Cell Proliferation Assay (Human Ki-67) for rapid, wash-free detection of a key proliferation marker]()
Promega UK Launches Lumit Cell Proliferation Assay (Human Ki-67) for rapid, wash-free detection of a key proliferation marker
New homogeneous, plate-based assay enables researchers to track hKi-67 in a simple add-and-read format, delivering robust and reproducible results in less time
Logistics
![Imara Sickle Cell Framework launches to coordinate diagnosis-to-treatment care across Africa]()
Imara Sickle Cell Framework launches to coordinate diagnosis-to-treatment care across Africa
Initial implementation begins in Uganda, Kenya and Côte d'Ivoire, connecting screening, diagnosis, referral and long-term management into a unified pathway as the continent accounts for nearly 80% of the global disease burden